Accessibility Menu
Telomir Pharmaceuticals logo

Telomir Pharmaceuticals(NASDAQ) TELO

Market Cap$79.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-77%
5 YearN/A
1 Year-50%
1 Month-7%
$1.22
+6.09%
+0.07Today
Telomir Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 1.152026-07-24
Telomir Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.6%USD 1.112026-07-17
1 month-6.5%USD 1.232026-06-24
3 month-17.86%USD 1.402026-04-24
Year to date-13.53%USD 1.332025-12-31
1 year-49.78%USD 2.292025-07-24
Since inception-77%USD 5.002024-02-09

Telomir Pharmaceuticals Financials at a Glance

Market Cap

$79.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.22M

EPS (TTM)

-$0.29

P/E Ratio

-3.94

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$1.22

Volume

1,951

Open

$1.18

Previous Close

$1.22

Daily Range

$1.17 - $1.22

52-Week Range

$0.89 - $2.19

Estimated Earnings Date

Sep 2, 2026

TELO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telomir Pharmaceuticals

Telomir develops medicines for age-related diseases and cancer. Its main product aims to help people recover from inflammation and chemotherapy. The company focuses on treatments that target the root causes of aging in cells.

Lab Bench to Bedside: What Telomir Sells

  • Telomir-1 (Zn-Telomir): An oral drug in development for age-related inflammation, cancer, and rare diseases. (0% of revenue; no sales yet)
  • Preclinical Research Services: All activities focus on research and development for Telomir-1. (0% of revenue)
  • Potential Applications: Targeting conditions like hemochromatosis, osteoarthritis, Wilson’s disease, type 2 diabetes, and post-chemotherapy recovery. (0% of revenue)

Growth Spurts and Strategic Moves

  • Changed name from Metallo Therapies to Telomir in October 2022.
  • Secured exclusive U.S. license for Telomir-1 from MIRALOGX in August 2023.
  • Formed partnerships with InSilico Trials, Recipharm, and others for research and manufacturing since 2023.
  • Announced planned merger with TELI Pharmaceuticals in 2025 to consolidate global rights.
  • Expanded research into new disease areas and optimized drug manufacturing in 2025.

What Makes Telomir a Bit Different

Telomir targets the underlying cell changes that drive aging and disease, not just symptoms. It relies on a network of research partners and contractors instead of a large in-house team. The company holds exclusive rights to its main drug candidate in the United States through 2043.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $1 million in Q3 2025, improving 80.9% from Q3 2024.
  • Cash used in operations was $927,265 in Q3 2025, down 7.5% from Q3 2024.
  • Cash balance was $7.3 million at December 31, 2025.

Bottom Line

Telomir remains a pre-commercial biotech focused on early-stage drug development. Its future depends on research progress and securing new funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2

CEO

Erez Aminov

Website

www.telomirpharma.com

Headquarters

Miami, FL 21205, US

TELO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-201.23%

Return on Capital

-165.00%

Return on Assets

-159.33%

Earnings Yield

-25.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$79.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

68.78M

Volume

1.95K

Avg. Volume

158.20K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$9.39M

EBITDA

-$9.22M

Operating Cash Flow

-$4.60M

Capital Expenditure

-$3.00

Free Cash Flow

-$4.60M

Cash & ST Invst.

$5.56M

Total Debt

$202.87K

Telomir Pharmaceuticals Performance Analysis

Telomir Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Telomir Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Telomir Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.03512.8%
20232023-12-31USD -0.441433.0%
20242024-12-31USD -0.5626.8%
20252025-12-31USD -0.33-41.2%
Telomir Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-132.2%
Q32025-09-3080.0%
Q42025-12-31-76.5%
Q12026-03-3150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$79.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$39.55M

N/A

Employees

2

N/A

Net Income

-$990.95K

+54.5%

EBITDA

-$989.69K

+54.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.56M

+1279.8%

Total Debt

$202.87K

+117.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$202.87K

+117.1%

Return on Assets

-1.59%

N/A

Return on Invested Capital

-1.89%

N/A

Free Cash Flow

-$1.77M

-105.5%

Operating Cash Flow

-$1.77M

-105.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EQEquillium, Inc.
$2.46-1.20%
INMBINmune Bio, Inc.
$1.73+6.79%
COEPCoeptis Therapeutics Holdings, Inc.
$10.99-8.57%
GNTAGenenta Science S.p.A.
$1.59+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About TELO

What is the current price of Telomir Pharmaceuticals?

Telomir Pharmaceuticals is trading at $1.22 per share.

What is the 52-week range for Telomir Pharmaceuticals?

Over the past 52 weeks, Telomir Pharmaceuticals has traded between $0.89 and $2.19.

How much debt does Telomir Pharmaceuticals have?

As of the most recent reporting period, Telomir Pharmaceuticals reported total debt of $202.87K.

How much cash does Telomir Pharmaceuticals have on hand?

Telomir Pharmaceuticals reported $5.56M in cash and cash equivalents in its most recent financial results.

What is Telomir Pharmaceuticals’s dividend yield?

Telomir Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services